Skip to main content

Table 2 Epidemiologic and economic results

From: Budget impact analysis of first-line treatment with pazopanib for advanced renal cell carcinoma in Spain

  Patients Pazopanib Sunitinib Difference Percent
Per patient and cycle pharmacological costs   €4,046 €4,904 -€858 -17.50%
Per patient annual (8 cycles) pharmacological costs   €32,365 €39,232 -€6,867 -17.50%
Per patient annual costs associated with AE management   €662 €974 -€312 -32.03%
Per patient overall annual costs   €33,027 €40,206 -€7,179 -17.85%
Year 2013      
Advanced RCC at diagnosis 854     
Progressions to advanced RCC 934     
Advanced RCC (favorable or intermediate risk) 1,591     
Pharmacological costs   €29,350,968 €35,578,198 -€6,227,230 -17.50%
Overall costs   €30,404,210 €37,127,832 -€6,723,622 -18.11%
Year 2014      
Advanced RCC at diagnosis 866     
Progressions to advanced RCC 948     
Advanced RCC (favorable or intermediate risk) 1,615     
Pharmacological costs   €28,925,945 €35,063,000 -€6,137,056 -17.50%
Overall costs   €29,963,935 €36,590,195 -€6,626,260 -18.11%
Year 2015      
Advanced RCC at diagnosis 878     
Progressions to advanced RCC 962     
Advanced RCC (favorable or intermediate risk) 1,638     
Pharmacological costs   €28,483,391 €34,526,553 -€6,043,162 -17.50%
Overall costs   €29,505,501 €36,030,382 -€6,524,881 -18.11%